Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vyvanse

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

Shire Basingstoke

Shire boosts rare disease portfolio with $260m Lumena deal

Acquisition of US company will bring two mid-stage candidates for rare liver diseases

- PMLiVE

Pharma companies back Rare Disease Day

Genzyme, Shire and more hold global campaigns today

The distressing impact of rare diseases

Much more needs to be done to address the problem of effective communications with stakeholders and adequate information for patients affected

- PMLiVE

Shire to file Vyvanse for binge-eating in Q3

Wants to mirror drug’s success as ADHD treatment

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

- PMLiVE

Shire elects new chair

Susan Kilsby to replace Matthew Emmens who retires

Shire Basingstoke

Shire faces $650m loss on Dermagraft sale

Sells struggling foot ulcer treatment to Organogenesis

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

Shire Basingstoke

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links